Cargando…
Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity
Most recombinant adeno-associated virus (AAV) capsids utilized in liver gene therapy have significant levels of pre-existing neutralizing antibodies in the human population. These neutralizing factors limit the patient pools eligible for receiving AAV-mediated therapies. AAV serotype 5 (AAV5) does n...
Autores principales: | Qian, Randolph, Xiao, Bin, Li, Juan, Xiao, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773954/ https://www.ncbi.nlm.nih.gov/pubmed/33426144 http://dx.doi.org/10.1016/j.omtm.2020.10.010 |
Ejemplares similares
-
Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity
por: Biswas, Moanaro, et al.
Publicado: (2020) -
Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain
por: Chakrabarty, Paramita, et al.
Publicado: (2013) -
Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice
por: Zou, Chenhui, et al.
Publicado: (2020) -
Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes
por: Gilkes, J.A., et al.
Publicado: (2015) -
Hair Cell Transduction Efficiency of Single- and Dual-AAV Serotypes in Adult Murine Cochleae
por: Omichi, Ryotaro, et al.
Publicado: (2020)